The 2015 ACMG/AMP sequence variant interpretation guideline provided a framework for classifying variants based on several benign and pathogenic evidence criteria, including a pathogenic criterion (PVS1) for predicted loss of function variants. However, the guideline did not elaborate on specific considerations for the different types of loss of function variants, nor did it provide decision-making pathways assimilating information about variant type, its location, or any additional evidence for the likelihood of a true null effect. Furthermore, this guideline did not take into account the relative strengths for each evidence type and the final outcome of their combinations with respect to PVS1 strength. Finally, criteria specifying the genes for which PVS1 can be applied are still missing. Here, as part of the ClinGen Sequence Variant Interpretation (SVI) Workgroup's goal of refining ACMG/AMP criteria, we provide recommendations for applying the PVS1 criterion using detailed guidance addressing the above-mentioned gaps. Evaluation of the refined criterion by seven disease-specific groups using heterogeneous types of loss of function variants (n = 56) showed 89% agreement with the new recommendation, while discrepancies in six variants (11%)
INTRODUCTION
In 2015, the American College of Medical Genetics and Genomics (ACMG) and the Association for Molecular Pathology (AMP) published a joint guideline that provides a framework for Sequence Variant Interpretation (SVI; Richards et al., 2015) . The guideline defined 28 criteria, each with an assigned code that addressed distinct types of variant evidence. Each criterion code was assigned a direction, benign (B) or pathogenic (P), and a level of strength: stand-alone (A), very strong (VS), strong (S), moderate (M), or supporting (P). Combining rules for these criteria were also proposed to determine the predicted pathogenicity of sequence variants.
The only criterion designated with very strong strength level for pathogenicity in the ACMG/AMP guideline was PVS1, which was defined as "null variant (nonsense, frameshift, canonical ±1 or 2 splice sites, initiation codon, single or multi-exon deletion) in a gene where loss-of-function (LoF) is a known mechanism of disease" (Richards et al., 2015) . A combination of this rule and only one moderate or two supporting pathogenicity criteria lead to a likely pathogenic or pathogenic classification, respectively in the original ACMG/AMP recommendations. Given the weighting of this criterion as very strong and the consequent impact of any potential inappropriate usage, detailed guidance on its application is critical. Despite addressing general considerations associated with PVS1 usage including disease mechanism, splice variant effects, nonsense-mediated decay (NMD), and alternative splicing, the ACMG/AMP guideline did not provide guidance for how to account for these considerations during variant assessment and determination of whether PVS1 was applicable. Additionally, while the ACMG/AMP guideline stated that criteria listed at one strength can be moved to another strength level using professional judgment, no guidance was provided regarding instances in which the strength level of PVS1 should be decreased to strong (PVS1_Strong), moderate (PVS1_Moderate), or supporting (PVS1_Supporting).
The NIH-funded Clinical Genome Resource (ClinGen) established the SVI working group (https://www.clinicalgenome.org/workinggroups/sequence-variant-interpretation/) to refine and evolve the ACMG/AMG rules for accurate and consistent clinical application, as well as harmonize disease-focused specification of the guidelines by Expert Panels (Gelb et al., 2018; Kelly et al., 2018) .
In this report, we provide detailed recommendations by the SVI working group for interpretation of the PVS1 criterion. These recommendations provide criteria for determining if LoF is a disease mechanism for the associated gene/disease and address variant type-specific considerations (nonsense, frameshift, initiation codon, invariant splice site, deletion, and duplication) in the context of gene structure and pathophysiologic mechanisms, such as NMD or alternative splicing. In addition, we assign varying modifications of PVS1 strength based on assimilation of the available evidence ("Guidance on how to rename criteria codes when strength of evidence is modified" can be found on the ClinGen SVI webpage).
Finally, 56 putative LoF variants of varying variant type and across multiple genes were curated by ClinGen disease-specific working groups to determine if the recommendations were easy to follow, accounted for all LoF scenarios encountered, and if the working group agreed with the specified PVS1 strength level for each tested variant.
METHODS
In July 2017, the SVI Working Group, representing clinical geneticists, genetic counselors, genomic researchers, and clinical laboratory geneticists, held a 2-day in-person meeting in Boston, MA to specifically refine and extend several ACMG/AMP criteria including the PVS1 criterion. During this meeting, the group outlined a detailed framework for evolving the previous PVS1 criterion into the current recommendations in this report. Subsequently, a smaller group within the ClinGen Hearing Loss (HL) Working Group continued further refinement of this rule through weekly conference calls and solicited feedback from the SVI Working group via monthly conference calls.
In October 2017, the SVI Working Group held a second in-person meeting at the American Society of Human Genetics (ASHG) meeting in Orlando, FL. During that meeting, the group finalized a first recommendation draft and provided comments for additional refinements that were addressed through the HL group and later approved by the SVI Working Group.
Throughout the PVS1 criterion refinement process, we used expert opinions, empirical data in the literature, and unpublished observations from participating research and clinical laboratories. In addition, to ensure comprehensive utility of the new rule, seven ClinGen Clinical Domain Working Groups (CDWGs) were asked to use this rule to classify five to 10 LoF variants each in their genes of interest (total 56 variants in 10 genes). Their feedback was then incorporated into the final PVS1 recommendations.
RESULTS

Recommendation for application of PVS1 criterion
The SVI working group has created a PVS1 decision tree (Figure 1) to guide curators on the applicable PVS1 strength level depending on variant type (duplication, deletion, splice site, nonsense/frameshift, and initiation codon) and variant features (such as predicted impact, location in the gene, and inclusion of impacted exon). The current decision tree format assumes that the gene/disease association is at a Moderate, Strong, or Definitive clinical validity level (Strande et al., 2017) and that LoF is an established disease mechanism (see "Disease Mechanism" section and 
Alternate transcripts and nonsense mediated mRNA decay (NMD) considerations
The predicted impact of a premature termination codon on an mRNA and/or a protein product depends on the location of the new termi- (Rivas et al., 2015) . This database also provides tissue-specific, exon-level RNA sequencing data with information on alternative splicing and exon skipping. In addition, splicing patterns can be better understood by navigating existing transcript isoforms for a given gene in databases like RefSeq, CCDS, Ensembl, and AceView (Casper et al., 2018; Harrison et al., 2017 
Variant type considerations Nonsense and frameshift variants
The first step in the interpretation process for nonsense and frameshift variants includes determination of the location of the new termination codon within the most biologically relevant transcript. As explained above, this is critical to determining if NMD is predicted to occur, or if the putative LoF variant is in a nonessential exon that is either alternatively spliced from the major transcript, enriched with high frequency LoF variants in the general population, and/or removes a downstream region that is not critical to protein function. Different combinations of these variables will lead to different outcomes with respect to using PVS1, at any strength level, or not at all as illustrated in Figure 1 .
Canonical ±1,2 splice variants
Mutations of the canonical ±1 or 2 splice sites-intronic variants within 1 or 2 nucleotides from the exon-are often presumed to have LoF effects. The major consensus nucleotides at the U2 spliceosome donor and acceptor sites are GT and AG, respectively. It is important to note that for those variants, the PP3 (in silico splicing prediction) criterion
should not be used to avoid double counting the same predictive evidence used to assign PVS1. When interpreting ±1,2 splice variants, it is useful to predict the impact that altered splicing may have on the protein reading frame (Figure 1 ). While it is challenging to precisely know the effects of splice site variants (e.g., skipped exon, use of a cryptic splice site, etc.) without RNA studies, it is useful to search for cryptic or newly generated splice sites as well as anticipate the impact of adjacent exon (i.e. exon whose canonical splice sites are impacted) skipping or cryptic splice site usage. This might guard against some possible outcomes that could rescue damaging effects of variants that are mostly assumed to be impactful.
First, one should assess nearby (±20 bp) sequences for any cryptic splice sites, as well as for a newly generated functional splice site at the variant site, that may reconstitute in-frame splicing. Next, one should determine if the nucleotide sequence of the adjacent exon is divisible by three and therefore could lead to an in-frame deletion in an otherwise intact transcript or if it is not divisible by three and would predict a frameshift if the exon is simply skipped. Then the consequence of use of any cryptic or newly generated splice sites as well as exon skipping should be assessed and the lowest strength of PVS1 should be applied among the scenarios.
Similar approaches to assessing NMD, the biological relevance of the exon and protein region, as described above for nonsense and frameshift variants, should then be applied (Figure 1 ). PVS1_Supporting should be applied.
Initiation codon variants
Exonic deletions
The reading frame and NMD considerations illustrated for the ±1,2 splice variants and the nonsense/frameshift variants (NMD only) are also applicable to single and multi-exon deletions. Whole gene deletions default to PVS1, assuming the gene in question meets the criterion for an LoF disease mechanism (Table 1) . Although application of PVS1 (at a very strong level) would not reach a pathogenic or likely pathogenic classification using the combining rules in Richards et al. (2015) , the SVI working group acknowledged that for a full gene deletion of a known haploinsufficient gene, a pathogenic classification is warranted as long as there is no conflicting evidence that would question the technical data or haploinsufficiency mechanism. It is relevant to note that in the Bayesian SVI formulation (Tavtigian et al., 2018) , a very strong criterion alone generates a posterior probability of 0.975, which is likely pathogenic. Based on these considerations, we recommend interpreting the PVS1 criterion for exonic deletions as shown in Figure 1 .
Intragenic duplications
In the clinical laboratory, duplications are most commonly identified through exon array, MLPA, CMA, or NGS-based algorithms. While the affected exon(s) may be readily identified using these technologies, the location of the duplicated region (i.e., intragenic or extragenic) is often unknown, which can in turn affect the pathogenicity of the variant.
PVS1
should not be applied to exonic or whole gene duplications that are known to be inserted outside the relevant gene or if the duplication is a full gene inserted tandemly (Figure 1) . If a duplication of a portion of the gene of a defined length is inserted in tandem, then one can predict if the reading frame will be disrupted leading to NMD, in which case PVS1 can be applied (Figure 1) . PVS1 at any level should not be used if NMD is unlikely (or unknown) to occur since the underlying duplications of certain protein regions are not typically as disruptive as are their corresponding deletions.
Although one cannot assume duplications are in tandem, current data suggest that at least 83% of duplications (including exon level) are in tandem (Newman, Hermetz, Weckselblatt, & Rudd, 2015; Richardson et al. 2018 ). Consequently, a duplication at an unknown insertion site is only downgraded one step to PVS1_Strong strength level provided it is predicted to shift the reading frame and cause NMD (Figure 1) . The location and exact length of the duplicated fragment are essential to predict the effect on the reading frame of the protein.
Uncertainty regarding a duplication length should preclude use of PVS1 given the inability to predict the effect on a protein's reading frame and therefore NMD.
Disease mechanism considerations
PVS1 is only applicable if LoF is a disease mechanism for the relevant gene/disease association, as recommended in the ACMG/AMP guidelines (Richards et al., 2015) . However, decisions regarding use of the PVS1 strength level should also take into consideration the strength of evidence supporting the LoF disease mechanism for a given gene. To provide guidance on how to weight a gene's disease mechanism,
we outline the general criteria as shown in Table 1 . This is intended to provide a general framework until there is gene-level expert-curated mechanism information.
In general, the PVS1_VeryStrong pathogenic criterion can only be applied as shown in Figure 1 if used for a predicted LoF variant in genes with definitive or strong disease associations (Strande et al., 2017 After reviewing the PVS1 pilot variant results, the SVI working group elected to retain the current PVS1 evidence strength levels since our recommendations are meant to be a general guidance across all disease areas. The differences in classification represent the appropriate application of disease and gene-level specifications based on expert knowledge.
CONCLUSION
The ACMG/AMP guidelines have been widely implemented by clinical laboratories and have been shown to promote consistent variant interpretation among laboratories; however, due to subjective interpretation of ACMG/AMP criteria, differences in their application still remain (Amendola et al., 2016; Harrison et al., 2017 ). ClinGen's SVI Working Group, which has taken on the task of refining and evolving the current ACMG/AMP guideline to improve consistency in usage, has created recommendations for interpreting predicted LoF variants (PVS1 criterion). As this criterion is the only one assigned a very Future work will provide additional guidance regarding the combination of PVS1 with other rules.
